Hello, everyone. Welcome to our First Full Year Results Presentation. As you will have seen, Haleon had an extraordinary year. Following our de-merger from GSK, we have remained intensely focused on building our track record of growth. As we close the fiscal year, I'm very proud to tell you about what our team has accomplished. Not only have we achieved the ambition of becoming the first-listed company 100% focused on consumer health, with a compelling purpose to deliver better everyday health with humanity, but we've done it while delivering quality growth across our categories, brands, and geographies. Simply put, we're executing the ambitious strategy we laid out at our Capital Markets Day. We produced the results we're announcing today by capitalizing on Haleon's competitive advantages.
I'm talking about our world-class portfolio of category leading brands, which are trusted by millions of consumers globally, as well as our ability to combine deep human understanding with trusted science. We have a clear strategy to drive growth. The first element of that strategy is to continue to drive more household penetration. We'll be aiming to increase the number of consumers in the categories where we compete. The second part of that growth strategy is capitalizing on new and emerging growth opportunities across channels and geographies, as well as by expanding our portfolio. We will develop these sources of growth by maintaining our strong focus on both execution and financial discipline to improve profitability. In turn, that will support our reinvestment in growth opportunities. Finally, acting responsibly is right at the heart of everything we do here at Haleon.
I say that not just because it's the right thing to do, but because it's good for business. Through the combination of all these factors, we are growing Haleon into an exceptional company and a category leader. Let's take a look at the results in more detail. We're happy with our overall performance this year, the highlight of which was our strong revenue growth. Our overall organic sales growth was up 9%. That's ahead of the guidance range of 8%-8.5% we provided at our Q3 update. Importantly, we saw a healthy balance of price and volume mix across the year, with price at 4.3% and 4.7% volume mix. These were several factors contributing to our sales performance, but I'd like to point out a few highlights.
Importantly, our Power Brands led the way with 10.1% growth and contributed close to 70% of the group's growth. Category leaders like Panadol, Theraflu, Otrivin, and Advil all performed particularly well. Local growth brands are up strongly. Brands including Caltrate, Robitussin, and ENO contributed to around 20% of overall growth. Over the course of the year, about 2/3 of our business either gained or maintained share. We're also making good progress on our commitment to bring down leverage. We generated strong cash flow, and our net debt leverage now stands at 3.6x. Moving to profits, our Adjusted operating margin came in at 22.8%, which is flat on a reported basis. Our full year Adjusted operating profit was up 6% at constant currency.
Our operating leverage, pricing, and integration synergies combined to offset the standalone costs, cost inflation, and adverse foreign exchange we saw during the period. You'll hear more about these financial metrics from Tobias in a minute. Despite the macroeconomic factors we've had to navigate, we're confident in the measures we've taken to manage the business. Looking at Q4 specifically. Price was healthy and volume mix was flat. We had a tough comparator from Q4 last year, where we saw significant uptick in volumes as a result of capacity coming on stream in North America and the impact of Omicron around the world. I continue to be optimistic about the resilience of our portfolio. Overall, the business has not been significantly impacted by move to private label or down-trading. In fact, in the U.S., we gained share on private label across the majority of our portfolio.
There are some areas in certain brand category combinations where there's been some down-trading. We're talking about things like preventative antacids and smoking cessation. The business continues to perform well. Encouragingly, the momentum we saw in Q4 has continued in the first couple of months of 2023. For me, that reaffirms my strongly held belief that Haleon, with our unique model, competitive advantages, compelling purpose to deliver better everyday health with humanity and great people, is well-positioned to manage through challenging times like this. I'd like to take a closer look at our portfolio performance. In oral health, we maintained our track record of market outperformance with 5.6% growth. In fact, sales growth has been running at roughly double the rate of the overall market with our three Power Brands, Sensodyne, Parodontax and Polident Poligrip, all gaining share.
Sensodyne delivered mid-single digit growth. While Parodontax and Polident Poligrip produced high single-digit growth. These results are underpinned by a series of winning innovations. As an example, we launched Sensodyne Complete Protection in 18 markets. Complete Protection is a brand-new formula that's proven to deliver superior cleaning. We also launched Poligrip Power Max Hold+ with its precision nozzle in more than 15 markets, it's already outperforming the overall category. The growth we've achieved through innovations like these has been supported through our geographic expansion. For instance, we launched Parodontax in both South Africa and India, we tailored the products to suit local consumers, applied excellent execution to achieve successful launch in market. That good global growth was partially offset by some COVID-19 weakness in China and the ongoing conflict in Russia and Ukraine. Overall, we're really encouraged by what lies ahead for oral health.
Let's look at vitamins, minerals, and supplements. Here, we had solid organic growth of 5%. The second half of the year wasn't quite as strong as the first, which we expected. That's a result of benefiting from new capacity coming on stream 12 months ago in North America. We also had some COVID-related spikes in demand last year. We're feeling really good about the subcategories we compete in and our portfolio of brands. Just look at Scott's, BeTotal, and CalSource. They're all local growth brands and all delivering double-digit growth. Our ability to keep innovating has increased our penetration with younger households, and you can really see what I mean when you look at Emergen-C Kidz in the U.S. and Caltrate Milk Calcium Gummies in China. We also got very encouraging growth from geographic expansion, especially in key markets like Middle East Africa and Latin America.
In India, we achieved a 10% market share within three months of launching our multivitamins on Amazon. We leveraged our trusted science, as we always do, to further differentiate ourselves from our competitors. Just look at the clinical study on Centrum Silver Adult Tablets. That study clearly demonstrated positive results on cognitive capabilities of people 65 and older. In the over-the-counter pain relief category, we delivered 8.9% growth. Here, the standout was Panadol, which continued to outperform on the back of a prolonged cold and flu season. Our agility was the key element to our success. Over the past few years, we have seen demand for Panadol across markets increase significantly from pre-COVID-19 times. We have doubled our production in that time to help meet the elevated demand while simultaneously having to navigate supply issues. We also showed excellence in execution.
Panadol's Take Care campaign was very successful. It launched in over 10 markets with an initial message focused on post-COVID vaccination benefits during the first half. The message was adapted for cold and flu season in the second half. Advil continued its strong U.S. performance with excellent market execution. As the RSV virus surged across Canada, we worked closely with the government to help parents deal with the unprecedented surge in medication needs for children with our Advil Kids brand. Voltaren generated low single-digit growth. That performance was driven by the trend that shows topical consumption to be lower when people are relying on more systemic pain relief. Nevertheless, we still delivered strong growth in the U.S., thanks in part to the second wave of our Voltaren Caregivers campaign in November.
A prolonged cold and flu season, combined with several new innovations and solid commercial execution, all contributed to organic sales growth in OTC respiratory of 32.6%. Importantly, we grew overall share in the respiratory category. Theraflu was an important contributor to our success here, thanks to improved penetration in the U.S. This was supported by innovative launches such as Theraflu Max Strength, which we brought to market early in the flu season with a full range across three different formats. Our solid commercial execution allowed the brand to perform strongly. In Digestive Health and Other, we increased organic sales growth by 2.9%, consistent with a typical historical run rate for what we usually see in this category. In fact, we saw mixed trends across the three segments. In Digestive Health, our brands in immediate relief antacid category, such as TUMS, saw growth.
We saw challenging conditions in the preventative antacid market, and that impacted Nexium. Skin health grew high single digits, while smoking cessation, which makes up about a quarter of the category and tends to be more volatile, declined. Since the demerger, we have successfully operated as a standalone business and maintained our focus on driving efficiency. At the same time, we want to remain agile enough to make the investments required to deliver positive returns. We have delivered the final Pfizer synergies, and we've taken the aggregate annual synergies to over GBP 600 million. Taking a step back from our financial performance, I'd like to take a minute to talk about running our business responsibly and how key that is to our strategy.
At Haleon, we're on the path to making everyday health more inclusive and accessible. We have a unique opportunity to create solutions to the social and environmental challenges that hold people back from improving their everyday health. We're continuing to progress against the environmental targets we set out at our Capital Markets Day, and I'm delighted to say that across our own sites, Haleon was 100% powered by a renewable electricity in 2022. We're also committed, as I've mentioned, to playing a leading role in making health more inclusive. Just one example of that is our collaboration with Microsoft to expand the functionality of the Seeing AI app for use on our products. That incredible tool helps consumers who are blind, have low vision or low literacy to access essential information on our labels.
After scanning the barcode on a Haleon product, the Seeing AI app audibly narrates the use and safety information for consumers to hear. These initiatives are just a few of the many ways we are staying true to our purpose to deliver better everyday health with humanity. We've made great strides on that front, and I'm encouraged by what else we have in store. As you can see, Haleon had an extraordinary year. We've executed our strategy, built on our track record, and delivered quality growth. With that, I'd like to hand it over to Tobias to talk you through the numbers and to show you how our strategy is delivering results across Haleon.
Thank you, Brian. Good morning, everyone. I will mostly focus on our adjusted results as this is the most meaningful way to understand our performance. A full reconciliation of our adjusted to IFRS results can be found in our results press release published today. Let's look at the headline numbers for 2022. We continue to deliver strong results, proving that our strategy across the business is delivering growth even in a difficult environment. Revenue of GBP 10.9 billion reflected 9% organic revenue growth, with a healthy balance of both positive volume mix and price. Adjusted operating profit of GBP 2.5 billion, up 5.9% constant currency, resulted in 22.8% margin, down 60 basis points, driven by adverse transactional foreign currency as well as the ramp up of standalone costs as expected and previously guided.
Finally, the business continued to be highly cash generative, with GBP 1.6 billion of free cash flow, including a GBP 435 million outflow, mainly related to separation costs. As a result, we finished the year with reduced leverage of 3.6x. Turning to the drivers of revenue growth. Revenue increased 13.8% to GBP 10.9 billion on a reported basis. There was a 500 basis points benefit from favorable foreign exchange, mainly related to sterling weakness against the US dollar and China's renminbi. Minor disposals carried out in the year as well as a decline in manufacturing services resulted in net 20 basis points drag on reported growth. All in all, we delivered 9% organic sales growth, importantly with 4.3% price and 4.7% volume mix.
Brian's gone through the growth drivers and performance by category. It's worth highlighting that our business has demonstrated resilience over the last two years, consistently growing in the 4%-6% range, even excluding the swings from cold and flu. As Brian mentioned, the year has started well. I'm particularly encouraged that pain relief and respiratory have continued to deliver good revenue growth despite tough comparatives. This reassures us that stock levels are healthy with no excess stock from the end of last year. It's fair to say, at least in the short term, growth is likely to be more weighted towards price than volume mix. Now let's take a deeper look at respiratory and VMS. Starting with respiratory and cold and flu.
As I said before, it's becoming increasingly difficult to split individual year-on-year movements given elevated cold and flu rates, as well as COVID or RSV symptoms which are flu-like in nature. The data on this chart shows cold and flu weekly industry sellout data for the U.S. market. The gray shaded area in this chart is pre-pandemic sales, which is indicative of a normal season. Low cold and flu sales in the summer and a higher level in the winter. The green and black line shows sales in 21 and 22, and the purple line is the first few weeks of 2023. While this data is for the U.S. market, we have seen broadly similar trends in other geographies.
First, starting in the middle of the chart, we saw sustained cold and flu demand through the summer ahead of pre-pandemic levels, and this was very different to 2019. When looking at this year's season at the end of 2022 and the beginning of 2023, you can see that demand spiked early in November, December, but came down in January and February. In the prior year season, across 2021 and 2022, the peak happened later at the very end of December, and then dropped down below pre-pandemic levels in February and March. This compares to 2019, where there was less of a peak, but higher consumption throughout the first quarter. It's fair to say a few weeks' data points tend not to tell the story of the full season. Note that this chart shows sellout data from pharmacies and retail outlets.
There's a mismatch to our sales as we largely stock up the market in Q3 ahead of the consumption peak. Stepping back, whilst there is and always will be some short-term volatility in cold and flu, nothing has changed in our view that. This remains an attractive category that remains relevant and where we have a high quality portfolio of leading brands. Coming back to VMS. The VMS market is fragmented with a number of subcategories such as nutrition, mineral supplements, and herbals, where we don't have a presence. Depending on which market definition you look at, some providers even include other products, for example, energy drinks, in their category definitions. Our portfolio is a focused part of the overall market in attractive sub-segments.
In the U.S., which is about 1/3 of our VMS business, you can see on this chart that we saw significant category demand, particularly for immunity products during COVID waves. The last wave created a strong comparator, which we are now lapping. There's also an element of seasonality in some subcategories which see higher demand during winter. As a reminder, globally, our business is more weighted towards Asia-Pacific, which is over 40% of our VMS revenue and grew high single digits. As Brian mentioned, VMS has shown strong growth supported by both Centrum and our range of local growth brands across all three regions. Turning now to our regional segment performance. We delivered strong organic revenue growth across all of our regions, all with a healthy balance of price and volume mix.
Our emerging markets, which are a third of our revenues, saw broad-based growth up 16%, with particular strength in India, Latin America, and the Middle East. Developed markets saw good growth, up 6%. Let's look at the regions in more detail. Starting with North America. Organic revenue increased 5.9%, with 2.9% price and 3% volume mix. During the final quarter, organic growth was 1.6%, with 3% price and a 1.4% decline in volume mix, which was driven by lapping of a tough comparative in 2021, where we increased the supply of Advil, Centrum, and Emergen-C. Volumes were impacted by a reduction in inventory provisions at the number of retailers, particularly towards the end of the year, along with the recall of TUMS, which now has been resolved. Sensodyne continued to perform well with consumption up mid-single digit for the year.
Our other growth driver, Parodontax, saw strong growth. This, combined with mid-single-digit growth in denture care, offset a decline in Aquafresh. VMS revenues were down low single digit with growth in Emergen-C, partly offsetting a decline in Centrum from the tough comparative I mentioned earlier. Pain relief was up high single digit given pricing and strong demand for Advil. As covered earlier, respiratory health was up in the mid-30s%, benefiting from sustained incidences of cold and flu. Adjusted operating margin increased 250 basis points to 26% and increased 130 basis points on a constant currency basis. Margin expansion was driven by strong pricing combined with productivity improvements, including SKU rationalization and improved logistics productivity, which, taken together, more than offset commodity and freight cost pressure and costs from being a standalone company.
It's worth bearing in mind that increase also reflects favorable comparatives as the prior year included site investments and some one-time manufacturing write-offs. Turning to Europe, Middle East, Africa, and Latin America. Organic revenue increased 10.9% with 6.4% price and 4.5% volume mix. In Q4, organic revenue was up 6.8% with 8.8% price and a 2% decline in volume mix. The decline in volume mix in Q4 largely reflected our reduced presence in Russia. Across the year, we saw strong growth in Middle East Africa driven by Sensodyne. In both Northern and Southern Europe, revenue was up high single digit with broad-based growth, with the exception of Germany, which was down. We are well underway in our plans to turn around this business. Looking at the categories, oral health saw good growth with both Sensodyne and Parodontax performing well.
Denture care continued to recover following the removal of lockdown restrictions. In VMS, there was high single-digit growth in Centrum and our local growth brands. Pain relief revenue was up mid-single-digit, reflecting double-digit growth in Panadol with a slight decline in Voltaren. Respiratory was strong, up over 30% following the strong cold and flu rebound in Q1. Digestive health and other saw sales up double-digit. Adjusted operating margin declined by 190 basis points or 200 basis points constant currency, largely driven by standalone costs, adverse transactional FX, which I'll explain in a moment, and a one-time adverse impact of stock and receivable write-downs related to our business in Russia and Ukraine. Higher commodity and freight costs were fully offset by strong operating leverage and efficiencies across the business. Finally, turning to Asia-Pacific.
Organic revenue increased 10.6%, with 2.6% from price and 8% from volume mix. During Q4, organic revenue growth was up 8.3% with 1.5% from price and 6.8% from volume mix. As expected, there was lower impact from pricing compared to other regions, given less pronounced inflationary pressures and price controls on certain OTC brands. Over the year, the region delivered good growth, with double-digit growth in pain relief and respiratory health. Whilst oral health and VMS were both up high single digit. China, our second-largest market, was up 7%, with performance impacted by the timing of COVID-19-related lockdowns. Adjusted operating margin decreased 100 basis points or 120 basis points at constant currency to 20.5%.
The decline was largely driven by increased investment in A&P, higher freight costs, along with costs from being a standalone company, which more than offset the strong operating leverage and efficiencies delivered during the year. Moving now to look at our operating performance. As mentioned, revenue increased 13.8%. Adjusted gross profit was slightly behind this at 12.8%, resulting in 50 basis points decline in margin. Strong increases in commodity and freight costs, along with negative transactional FX, could not fully offset, in percentage terms, strong pricing, synergies, efficiencies, and mixed benefits. Adjusted operating profit increased 13.8% or 5.9% at constant exchange rates. I will now go through the drivers of Adjusted Operating margin.
As I mentioned, we delivered GBP 2.5 billion of Adjusted operating profit, resulting in a flat margin of 22.8% on a reported basis. Our margin was slightly below guidance shared at Q3 when I last updated you. This was mainly driven by a 5% movement in the US dollar and volatility in emerging market currencies against sterling by the end of the year, which reduced the translational benefit on margin, and transactional losses of about 30 basis points that came in at the upper end of our expectation range. As a reminder, as part of GSK, we did not hedge transactional exposure. As an independent company, we're building capability in this area, and as such, we expect this impact to reduce over time. Looking at the bridge in more detail.
In 2021, when we were a JV, we had a 22.8% margin. As a standalone company, we incurred new costs which were at the upper end of the GBP 175 million-GBP 200 million range, which I guided to. We also changed our accounting application for SaaS, given the majority of our software is in the cloud rather than on-premise. Both these had a net 230 basis points drag on operating margin, which was largely offset by the final delivery of Pfizer synergies across the business. Those were ahead of the GBP 120 million I expected for the year. The 9% organic growth resulted in 40 basis points positive operating leverage, with the business absorbing inflationary cost pressures and significant freight costs as we shipped for unexpectedly strong demand.
We also incurred higher staff incentive costs for sales results and cash flow being stronger than anticipated. A&P spend for the year was flat constant currency. It is worth taking a moment to reflect on a number of factors which impacted the spend. First, we ceased advertising in Russia. Second, there were savings and benefits in non-working A&P. For example, from bringing production in-house and negotiations capitalizing on our scale. Importantly, our consumer-facing A&P spend, excluding Russia, was up 6%. Disproportionately supporting our Power Brands and local growth brands. Taken together, this reflects an unusual year for A&P spend, which I expect will increase in 2023 more in line with the model I laid out at the Capital Markets Day.
In terms of FX, we had a 30 basis points headwind from transactional FX losses, largely from our manufacturing facilities in Switzerland and our operations in emerging markets, where there is a mismatch between our trading currencies and the currencies where we purchase our raw materials and manufacture goods. Naturally, this will also impact 2023, particularly in the first half. Beyond this, there was also GBP 171 million or 60 basis points benefit from movements in foreign exchange rates on a translational basis. Taken together, this resulted in a 14% increase in Adjusted operating profit to a 22.8% operating margin. Taking you through the other items in the P&L, our interest cost charge of GBP 207 million does not reflect a normal full year of interest costs, given we issued bonds in March.
As such, we had GBP 258 million of expense related to the gross debt, partly offset by interest income of GBP 51 million, mainly related to the on lend of funds to GSK and Pfizer before the demerger. For 2023, I currently expect a net interest charge of around GBP 350 million, reflecting a full year of carrying the bonds and the absence of interest income we received in 2022. Our Adjusted tax charge was GBP 506 million, representing an effective tax rate of 22.3%. For the full year 2023, I expect the Adjusted effective tax rate to be between 23% and 24%, reflecting increases in the UK, US, and Switzerland. Overall, this resulted in an Adjusted earnings per share of GBP 0.184, up 3%. Turning to the adjusting items.
As guided, the year was heavily impacted by the cost to separate Haleon and the listing of the company. Taking these in turn. First of all, there was a GBP 129 million non-cash impairment charge driven by a movement in discount rates which impacted Preparation H, given the low headroom we had on this brand relative to others. Separately, we impaired a brand that was largely sold in Russia and Ukraine. Restructuring costs were significantly lower at GBP 41 million as we reach the end of the Pfizer integration. As guided, we incurred the majority of separation and admission costs in 2022 at GBP 411 million. As you'd expect, these costs will be significantly lower going forward. Moving to look at cash. Our business model is highly cash generative, and we are very focused on cash.
For the year, Free cash flow was GBP 1.6 billion, which included a GBP 435 million of cash outflow from separation, restructuring, and disposals. During the year, there are several key items to note which impacted the cash flow. The cash tax in 2022 was abnormally low compared to our P&L tax charge, largely due to refunds received related to prior years. Going forward, our Adjusted P&L tax rate is indicative of our effective cash tax rate. The net interest payment of GBP 144 million differs from our P&L charge, largely due to the timing of coupon payments on our bonds, which are mainly in September and March. The cash interest cost will catch up with the charge in the P&L from this year onwards.
As expected, we had an outflow of GBP 48 million for non-controlling interests, mainly related to our joint ventures in China and Taiwan. Net CapEx was GBP 292 million, nearly double the level of last year. This is simply due to the prior year having GBP 113 million of higher disposal proceeds. Net CapEx remained in line with prior guidance at 3% of sales, with spend focused on manufacturing sites, technology, and automation. Turning to Haleon's debt and liquidity profile. As a reminder, pre-separation, we secured our long-term capital structure with the issuance of just over GBP 9 billion of notes and a GBP 1.5 billion term loan with no financial covenant. Most of our debt is long-term bonds with a weighted average duration of 7.8 years.
Since demerger, we have fully repaid our GBP 1.5 billion term loan through a combination of operational cash flows and GBP 300 million of commercial paper issuance. Finishing the year with leverage of 3.6x net debt to Adjusted EBITDA and net debt of GBP 9.9 billion. This compares to net debt of GBP 10.7 billion at separation. Looking at our debt portfolio in more detail. During the fourth quarter, we swapped GBP 0.9 billion of debt into China's renminbi, which allowed us to even better align our currency mix of debt with our currency mix of revenue. At the end of the year, our net debt was 87% fixed and 13% floating.
We had GBP 2.5 billion of liquidity at the end of the year, made up of GBP 2.2 billion of undrawn bank facilities and GBP 0.6 billion in net cash, less the GBP 0.3 billion of commercial paper outstanding. Given our strong cash generation, I now expect to reach our leverage target of less than 3x net debt to Adjusted EBITDA during 2024, somewhat earlier than I guided to at the Capital Markets Day last year. Let me turn to our outlook for 2023. We expect to achieve organic sales growth in the 4%-6% range, in line with our medium-term outlook. We see another year of positive operating leverage, which along with efficiencies, will more than offset investment in the business and cost inflation.
If current exchange rates hold, this will result in a broadly flat Adjusted operating margin after around 40 basis points of adverse transactional FX. As I mentioned previously, interest expense is expected to be around GBP 350 million, and we expect an estimated tax rate on adjusted profit in the range of 23%-24%. In summary, Haleon is delivering strong performance, proof that our model outlined at the Capital Markets Day is delivering. We drove very strong Free cash flow generation and have made good progress on bringing our leverage down. We will continue to invest in our brands, underpinning our confidence to deliver on guidance. With that, I will hand back to Brian.
Thanks, Tobias. Before I close, I wanna spend 2 minutes taking you through the next exciting phase of our journey. We are already seeing the benefits of being an independent company. We have a highly engaged board with rich consumer experience alongside an experienced management team. As you'd expect, we've been engaged collectively in discussing our strategy. We came out of that with absolute confidence in the potential of the business and are more excited than ever about our future. As you can imagine, as we work towards our separation from GSK, our focus was on ensuring continuity for the business. Now, fully up and running as an independent company, we have the opportunity to drive a more agile, productive, and effective organization.
As part of that effort, we announced today that we will generate around GBP 300 million of gross annualized savings, largely in 2024 and 2025. We will use these savings to drive investment and growth across the portfolio, as well as allow us to offset cost pressure. We have also identified further opportunities to drive growth across our portfolio. We believe that our Power Brands will continue to drive disproportionate growth through better household penetration and through opportunities for geographic expansion. We see opportunities to drive even more growth across our local growth brands. As we've explained, these local growth brands represent around 20% of our overall sales, and we expect them to see disproportionate growth. We plan to fully invest behind these opportunities we've identified. We've also been clear that we will target bolt-on acquisitions.
We will also be reviewing brands that might be right for divestment in areas where we see more limited growth opportunities. In all cases, we will only do things that drive long-term shareholder value. Taken together, these initiatives reinforce and underpin my confidence in delivering our medium-term guidance. We will provide more details on all these initiatives as we go through the year. Thank you for your continued interest and support.